Multi-omics Biomarkers

Uses

Highlighted claims

• Exploratory biomarker analyses include genomic, transcriptomic, proteomic, metabolomic, and exosome measures from blood and urine, intended to identify treatment responders. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Whole genome sequencing of all participants at baseline is intended to identify genomic predictors of bumetanide treatment response. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Resting-state EEG is used as an exploratory biomarker to assess network-level excitation/inhibition balance, including power spectral density across theta, alpha, beta, and gamma bands. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• NKCC1 and KCC2 expression in peripheral blood mononuclear cells is considered a promising biomarker, based on evidence of dysregulation in epilepsy, spinal cord injury, and schizophrenia. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial